Relafen 750, structurally known as naproxen, represents a important case study from a pharmaceutical pharmacy standpoint. It's exhibits its therapeutic effect primarily by blocking the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby suppressing prostaglandin formation. The specific inhibition of COX-2, compared to older NSAIDs